The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of ruxolitinib, temozolomide, and radiation in high-grade gliomas.
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - CytoDyn; doctible; MedInnovate Advisors LLC; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - Apollomics; Bayer; Celularity; GlaxoSmithKline; InSightec; Janssen; KIYATEC; Novocure; Nuvation Bio; Prelude Therapeutics; SDP Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst)
 
Yasmeen Rauf
No Relationships to Disclose
 
Glen Stevens
Consulting or Advisory Role - • EBSCO INDUSTRIES, INC
 
David M. Peereboom
Honoraria - Elsevier
Consulting or Advisory Role - Orbus Therapeutics; Sumitomo Dainippon Pharma Oncology, Inc.
Research Funding - Apollomics; Bayer; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Karyopharm Therapeutics; Karyopharm Therapeutics; Mylan (Inst); Neonc Technologies (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics; Stemline Therapeutics (Inst)